In vitro metabolism of the REV‐ERB agonist SR‐9009 and subsequent detection of metabolites in associated routine equine plasma and urine doping control samples
- 5 July 2021
- journal article
- research article
- Published by Wiley in Drug Testing and Analysis
- Vol. 14 (1) , 169-174
Abstract
SR‐9009 is a synthetic compound widely available to purchase online as ‘supplement’ products due to its potential performance‐enhancing effects, presenting a significant threat with regard to doping control in sport. In vitro metabolism with equine liver microsomes was performed to identify potential targets for detection of SR‐9009. Six metabolites were identified, with the most abundant consisting of N‐dealkylated metabolites (M1–M3). The addition of the identified metabolites to high‐resolution accurate mass databases resulted in a positive finding for the N‐dealkylated metabolite M1 of SR‐9009 in an associated plasma and urine doping sample. Liquid chromatography–high‐resolution mass spectrometry was used to verify the presence of the N‐dealkylated metabolite (M1) in both matrices, with a low concentration of the parent compound and additional N‐desalkyl metabolites (M2 and M3) detected in the plasma sample as supporting evidence of administration. To the best of the authors' knowledge, this is the first report of an adverse analytical finding in an equine sample for SR‐9009 or its metabolites in equine doping control.Keywords
This publication has 6 references indexed in Scilit:
- Equine metabolism of the selective androgen receptor modulator AC‐262536 in vitro and in urine, plasma and hair following oral administrationDrug Testing and Analysis, 2020
- Investigation of the metabolism of the selective androgen receptor modulator LGD‐4033 in equine urine, plasma and hair following oral administrationDrug Testing and Analysis, 2019
- SR9009 has REV-ERB–independent effects on cell proliferation and metabolismProceedings of the National Academy of Sciences, 2019
- A further insight into the metabolic profile of the nuclear receptor Rev‐erb agonist, SR9009Drug Testing and Analysis, 2018
- In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011International Journal of Molecular Sciences, 2016
- Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonistsNature, 2012